Genmab A-S (spons. ADRs) Aktie

18,80 EUR ±0,00 EUR ±0,00 %

29.05.2025

FSE

21,34 USD +0,14 USD +0,64 %

29.05.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

KGV11,78Div. Rendite0,00%

WKNA1WZYB

ISINUS3723032062

SymbolGMAB

Genmab A-S (spons. ADRs) Aktien News

Sortieren:Datum Meistgelesen

27.05.25GlobeNewswireGenmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference

26.05.25GlobeNewswireTransactions in Connection with Share Buy-back Program

22.05.25GlobeNewswireGenmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

WerbungGenmab A-S (spons. ADRs)-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

21.05.25GlobeNewswireGenmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference

20.05.25GlobeNewswireCapital Increase in Genmab as a Result of Employee Warrant Exercise

19.05.25GlobeNewswireTransactions in Connection with Share Buy-back Program

14.05.25GlobeNewswireGenmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

12.05.25GlobeNewswireTransactions in Connection with Share Buy-back Program

08.05.25GlobeNewswireGenmab Announces Financial Results for the First Quarter of 2024

05.05.25GlobeNewswireTransactions in Connection with Share Buy-back Program

02.05.25GlobeNewswireGenmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follic

28.04.25GlobeNewswireTransactions in Connection with Share Buy-back Program

22.04.25GlobeNewswireTransactions in Connection with Share Buy-back Program

16.04.25ZacksShould Value Investors Buy Genmab (GMAB) Stock?

15.04.25GlobeNewswireGenmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

14.04.25GlobeNewswireTransactions in Connection with Share Buy-back Program

10.04.25GlobeNewswireGenmab A/S Share Capital Reduction

09.04.25BenzingaWhat Analysts Are Saying About Genmab Stock

07.04.25GlobeNewswireTransactions In Connection with Share Buy-back Program

01.04.25GlobeNewswireTransactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

31.03.25GlobeNewswireTIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

31.03.25GlobeNewswireTransactions in connection with share buy-back program

27.03.25BenzingaJapanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

27.03.25GlobeNewswireTIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

25.03.25GlobeNewswireGenmab Announces Initiation of Share Buy-Back Program

22.03.25GlobeNewswireGenmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

17.03.25GlobeNewswireInvestigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

12.03.25GlobeNewswireTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

12.03.25GlobeNewswireConstitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

11.03.25BenzingaBreaking Down Genmab: 4 Analysts Share Their Views

10.03.25GlobeNewswireGenmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

04.03.25GlobeNewswireTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

28.02.25GlobeNewswireTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

28.02.25GlobeNewswireGrant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

25.02.25GlobeNewswireCapital Increase in Genmab as a Result of Employee Warrant Exercise

20.02.25GlobeNewswireEPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

19.02.25GlobeNewswireGenmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference

13.02.25GlobeNewswireNotice to Convene the Annual General Meeting of Genmab A/S

12.02.25GlobeNewswireGenmab Files Annual Report with the U.S. Securities and Exchange Commission

12.02.25GlobeNewswireGenmab Publishes 2024 Annual Report

Genmab A-S (spons. ADRs) News

Genmab A-S (spons. ADRs) News: auf dieser Seite finden Sie alle Genmab A-S (spons. ADRs) News und Nachrichten zur Genmab A-S (spons. ADRs) Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Genmab A-S (spons. ADRs) News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Genmab A-S (spons. ADRs) News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.